High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
20.17M
+5.73%
-0.160
-30.39%
19.30M
+10.26%
-0.176
-37.21%
21.65M
+10.66%
-0.154
-32.94%
Estimates Revision
The market is revising Upward the revenue expectations for Sight Sciences, Inc. (SGHT) for FY2025, with the revenue forecasts being adjusted by 3.51% over the past three months. During the same period, the stock price has changed by 126.02%.
Revenue Estimates for FY2025
Revise Upward
+3.51%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-24.01%
In Past 3 Month
Stock Price
Go Up
+126.02%
In Past 3 Month
7 Analyst Rating
Wall Street analysts forecast SGHT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGHT is 5.17 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
4 Hold
0 Sell
Moderate Buy
Current: 8.340
Low
4.00
Averages
5.17
High
7.00
Current: 8.340
Low
4.00
Averages
5.17
High
7.00
Morgan Stanley
Patrick Wood
Equal Weight
maintain
$6 -> $8
2025-12-02
New
Reason
Morgan Stanley
Patrick Wood
Price Target
$6 -> $8
2025-12-02
New
maintain
Equal Weight
Reason
Morgan Stanley analyst Patrick Wood raised the firm's price target on Sight Sciences to $8 from $6 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
Piper Sandler
Matt O'Brien
Neutral
maintain
$4 -> $5
2025-11-07
Reason
Piper Sandler
Matt O'Brien
Price Target
$4 -> $5
2025-11-07
maintain
Neutral
Reason
Piper Sandler analyst Matt O'Brien raised the firm's price target on Sight Sciences to $5 from $4 and keeps a Neutral rating on the shares. The firm notes the company reported Q3 results that beat expectations on the top and bottom-line and raised its full year 2025 revenue guidance to $76M-$78M, or by about $3.0M at the midpoint. Piper was pleased to see the outperformance in the surgical glaucoma segment as the company was able to grow that business +6% year-over-year in the quarter, which was much better than expected.
Lake Street
Buy
maintain
$5 -> $7
2025-10-21
Reason
Lake Street
Price Target
$5 -> $7
2025-10-21
maintain
Buy
Reason
Lake Street raised the firm's price target on Sight Sciences to $7 from $5 and keeps a Buy rating on the shares after two Medicare administrative contractors finalized coverage policies for Sight Sciences' Dry Eye Disease treatment system, TearCare. The firm sees this as "a significant positive that could be a driver of outperformance," the analyst tells investors.
Citi
Neutral
maintain
2025-08-21
Reason
Citi
Price Target
2025-08-21
maintain
Neutral
Reason
Citi raised the firm's price target on Sight Sciences to $4.50 from $3.60 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology space following the Q2 reports. Citi views the overall sector as healthy and opened "positive catalyst watches" on Edwards Lifesciences (EW) and Penumbra (PEN). The analyst also added iRhythm (IRTC) to its medtech top picks list, alongside Boston Scientific (BSX) and Edwards.
Lake Street
Hold
to
Buy
upgrade
$3 -> $5
2025-08-08
Reason
Lake Street
Price Target
$3 -> $5
2025-08-08
upgrade
Hold
to
Buy
Reason
Morgan Stanley
Equal Weight
maintain
$3 -> $4
2025-07-15
Reason
Morgan Stanley
Price Target
$3 -> $4
2025-07-15
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Sight Sciences to $4 from $3 and keeps an Equal Weight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Sight Sciences Inc (SGHT.O) is -13.55, compared to its 5-year average forward P/E of -7.27. For a more detailed relative valuation and DCF analysis to assess Sight Sciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-7.27
Current PE
-13.55
Overvalued PE
-2.75
Undervalued PE
-11.79
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-6.41
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.34
Undervalued EV/EBITDA
-13.15
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
5.90
Current PS
0.00
Overvalued PS
11.70
Undervalued PS
0.10
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
SGHT News & Events
Events Timeline
(ET)
2025-11-11
07:04:50
Sight Sciences Reveals Findings from Three Studies on Glaucoma Treatment
2025-11-06 (ET)
2025-11-06
18:01:09
Sight Sciences announces Q3 earnings per share of 16 cents, below consensus estimate of 26 cents.
2025-10-17 (ET)
2025-10-17
07:09:22
Sight Sciences to announce revised revenue projections during Q3 earnings call
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/aa1dfbafc510320b742c362c7c7d583186eea003b5fdeb813722a5b53b732d60.jpg)
Preview
4.0
11-12NASDAQ.COMSight Sciences (SGHT) Receives Upgrade to Buy: Key Information You Need to Know
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/a194f1ef3a267df4f2527bd966fc6e4f166d53997c3376044e8bd526e0f2c96c.jpg)
Preview
9.5
11-07NASDAQ.COMSight Sciences (SGHT) Q3 Earnings: Analyzing Key Metrics Against Expectations
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/2eda5fad69617f030ce208e320c845367aefe0c0e0be4612ab8f916c5fdc6713.png)
Preview
7.0
09-09BenzingaUnitedHealthcare Includes Sight Sciences OMNI System in Covered Glaucoma Surgery Options
Sign Up For More News
People Also Watch
FAQ
What is Sight Sciences Inc (SGHT) stock price today?
What is Sight Sciences Inc (SGHT)'s business?
What is the price predicton of SGHT Stock?
What is Sight Sciences Inc (SGHT)'s revenue for the last quarter?
What is Sight Sciences Inc (SGHT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Sight Sciences Inc (SGHT)'s fundamentals?
How many employees does Sight Sciences Inc (SGHT). have?